Drug Profile
Nateplase
Alternative Names: Milyzer; MMR 701; TepaseLatest Information Update: 08 Oct 2007
Price :
$50
*
At a glance
- Originator Nihon Schering
- Developer Bayer Yakuhin; Mochida Pharmaceutical
- Class Plasminogen activator enzymes; Thrombolytics
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Myocardial infarction
Most Recent Events
- 12 Feb 1997 Launched for Myocardial infarction in Japan (IV-injection)
- 22 Jul 1996 Registered for Myocardial infarction in Japan (IV-injection)
- 13 Dec 1995 MMR 701 is now called nateplase